Peptides for healing and recovery: what the evidence supports — and what it doesn’t.
The shoulder that used to settle down in a week now takes a month. The knee complains for the rest of the season. Somewhere past forty, recovery stopped being automatic — and the internet has an answer ready. Peptides studied for tissue repair are a real research category, and they are also one of the most oversold things in men’s health right now. This page separates the two: what this category is, how strong the human evidence actually is, and where it belongs in a plan that has to work.
Castellano Health Institute · Serving Orange County
A signal to a system — not a replacement of one.
Peptides are short chains of amino acids the body uses as signaling molecules — internal messages that tell specific cells to do specific things. The tissue-repair family is the group studied for soft-tissue, tendon, ligament, and post-injury healing. A related group is studied for recovery and sleep quality; those work by signaling the pituitary to support the body’s own production rather than replacing anything.
That distinction matters more than it sounds. Replacement therapy corrects a measurable deficiency — the level is low, so it gets restored and then tracked. This category does something different: it nudges a process the body already runs. Which means the honest questions are whether that nudge is measurable in people, how large it is, and whether it holds up outside a laboratory. Those are the questions the rest of this page answers, and the broader category map lives on the peptide therapy page.
No specific compound is named here, and that is deliberate. What is appropriate to compound and prescribe shifts with current regulatory guidance, so the conversation about any particular protocol belongs in the visit, against your labs — not on a published menu that goes stale.
It isn’t in your head. Tendons really do change with age.
The published work on tendon aging is reasonably consistent: the structure and composition of the extracellular matrix change over time, cell density and metabolic activity in the tendon decline, and cellular senescence increases. Taken together, those changes make age a recognized risk factor for tendinopathy and for slower, less complete healing after an injury. So the thing you are noticing has a real biological substrate behind it.
That is worth saying plainly, because it is where most men stop reading and start shopping. A genuine mechanism does not automatically mean a marketed product corrects it. It means the complaint is legitimate and deserves a real workup — which frequently turns up something more actionable than a stubborn tendon: an unaddressed hormone deficiency, a metabolic picture that is working against repair, or a structural problem that needs imaging rather than a protocol.
An honest gradient, not a verdict.
“Does it work” is the wrong shape of question for this category, because the evidence sits at four very different levels depending on what is being asked. Here is where each one actually stands.
| Where the evidence sits | What has actually been shown | How it’s treated here |
|---|---|---|
| Cell and animal models | Most of the published tissue-repair peptide work lives here — signals in laboratory and animal studies of tendon, muscle, and wound healing. | Treated as promising, not as proof. Encouraging preclinical work is where a good idea starts, not where it finishes. |
| Small or uncontrolled human reports | A handful of human case reports and small series exist for some tissue-repair uses. They generally lack control groups. | Read as hypothesis-generating. Uncontrolled results are the kind that most often fail to survive a proper trial. |
| Dose, frequency, and duration | Not established in the published musculoskeletal literature. A 2026 narrative review in a peer-reviewed sports-medicine journal said so directly. | A reason for conservative, time-limited protocols with a scheduled re-evaluation — not indefinite use. |
| Progressive loading, sleep, protein, time | The strongest evidence base in recovery medicine, and the least marketed. This is the part that is genuinely well studied. | The foundation. Nothing in the peptide category substitutes for it, and adjuncts get considered only once it is in place. |
Put simply: the preclinical work in this space is real and worth following, and the human work is not yet strong enough to promise anyone a faster recovery. A 2026 narrative review in a peer-reviewed sports-medicine journal, written for orthopaedic physicians fielding exactly these questions, concluded that the clinical evidence supporting routine use is currently lacking and that dosing and duration remain unknown.
That is a genuinely uncomfortable thing for a clinic to publish on a page about a service it offers. It is also the reason to trust what happens in the visit. A physician who will tell you the data is thin when it is thin is the same physician who will tell you when something is worth trying — and you can believe the second sentence because of the first. The same posture drives how anabolic steroid care is handled here.
The recovery window most men are quietly losing.
A lot of what men call slow recovery is really disrupted sleep. Two things here are well established. First, deep slow-wave sleep declines measurably with age — a large meta-analysis of objectively recorded sleep across the lifespan found slow-wave sleep, total sleep time, and sleep efficiency all falling in adults as the years go on. Second, sleep is a primary recovery window, which is why sleep is treated as a front-line lever in the sports recovery literature rather than an afterthought.
Peptides studied for sleep architecture and daily recovery exist, and this is the narrowest evidence base of anything on this page. Some of what is published is preclinical; the human work is limited. So the register here stays modest on purpose. Before any of that is a conversation, the ordinary causes get looked at: shift work and travel load, alcohol close to bedtime, screening for sleep apnea in a man who snores and wakes unrested, and whether a hormone deficiency is disrupting sleep in the first place.
Those are the levers with real evidence behind them, and they are free. If they have already been addressed and sleep is still broken, that is a different and more interesting conversation — one that starts with bloodwork, not with a protocol.
An adjunct can’t carry the foundation.
This is the beat most pages in this category skip. Nothing studied for tissue repair compensates for the following, and a protocol layered on top of them is money spent on the wrong problem:
- Sleep debt — the recovery window itself, which no protocol replaces
- Training load that has outrun what the tissue can currently absorb
- Protein intake and nutrition that are not supporting repair
- A structural injury that needs imaging, rehab, or a surgical opinion
- An unaddressed hormone deficiency underneath the recovery complaint
That last one is the common miss. Recovery complaints in men past forty are frequently a hormone problem in disguise, and correcting a documented deficiency does more than an adjunct ever will. Which of the two is actually load-bearing for you is worked through on peptides versus TRT, and settled in the visit with labs on the table.
Cycled and re-evaluated — never on autopilot.
When peptide therapy does belong in a plan, the structure is the same every time. Bloodwork comes first, because without baseline values there is nothing to anchor a recommendation to and nothing to measure against later. The history and the injury picture get reviewed in the same visit — a one-hour sit-down, with Dr. Castellano, not a form and a follow-up call.
From there, protocols in this category typically run in blocks of roughly 8 to 12 weeks followed by a genuine re-evaluation, rather than an indefinite refill. Cycling is not a marketing flourish; it is the direct consequence of the evidence gap described above. When duration is not established in the literature, the responsible move is a defined block with a scheduled checkpoint. If nothing meaningful has changed at that checkpoint, the protocol changes or it stops.
What that rules out is the model this category is best known for: continuous monthly auto-shipment with no lab rechecks and no one reading the results. That is not peptide therapy under medical management — it is an unregulated transaction with a subscription attached. Longer-term recovery and healthy-aging work is covered on the anti-aging page, and the safety and oversight side is broken down on are peptides safe.
What men ask about healing and recovery.
Don’t see yours? Call the office and ask Dr. Castellano directly.
Do peptides help injuries heal faster?
What about peptides for joint pain?
Peptides for sleep — is that real?
How long before anything changes?
Is this instead of physical therapy?
Do I need labs first?
Can this run alongside testosterone therapy?
Related in the peptides knowledge cluster.
Peptide Therapy with Dr. Castellano
The service page — the categories, the honest primer, and how a protocol gets evaluated.
Peptides vs. TRT
Which problem each one actually solves — and which is load-bearing for you.
Are Peptides Safe?
Side effects, oversight, and where the risk in this category actually sits.
Anti-Aging & Healthy Aging
The wider evaluation behind recovery, energy, and how you age from here.
Find out what’s actually slowing you down.
A recovery that has gotten worse is a symptom, and it is worth finding the cause before choosing a tool. Call the office to schedule a consultation — a one-hour sit-down with Dr. Castellano, board certified by the American Board of Family Medicine and the American Board of Anti-Aging & Regenerative Medicine, with your bloodwork on the table. If peptide therapy is a reasonable part of the answer, you will hear exactly where the evidence for it stands. If it is not, you will hear that first.
Mon–Fri 9 AM – 5 PM · Serving Orange County